Investigational Drug Information for MGL-3196
✉ Email this page to a colleague
What is the drug development status for MGL-3196?
MGL-3196 is an investigational drug.
There have been 13 clinical trials for MGL-3196.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2019.
The most common disease conditions in clinical trials are Fatty Liver, Non-alcoholic Fatty Liver Disease, and Liver Diseases. The leading clinical trial sponsors are Madrigal Pharmaceuticals, Inc., Celerion, and Horizon Health Network.
There are six US patents protecting this investigational drug and one hundred and four international patents.
Summary for MGL-3196
| US Patents | 6 |
| International Patents | 104 |
| US Patent Applications | 47 |
| WIPO Patent Applications | 33 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 2 (2019-03-01) |
| Vendors | 40 |
Recent Clinical Trials for MGL-3196
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Madrigal Pharmaceuticals, Inc. | Phase 3 |
| A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients | Madrigal Pharmaceuticals, Inc. | Phase 3 |
| Drug Interaction Study of MGL-3196 With Clopidogrel | Madrigal Pharmaceuticals, Inc. | Phase 1 |
Clinical Trial Summary for MGL-3196
Top disease conditions for MGL-3196
Top clinical trial sponsors for MGL-3196
US Patents for MGL-3196
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MGL-3196 | See Plans and Pricing | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | Madrigal Pharmaceuticals, Inc. (West Conshohocken, PA) Hoffmann-La Roche Inc. (Little Falls, NJ) | See Plans and Pricing |
| MGL-3196 | See Plans and Pricing | Thyroid hormone analogs | Hoffmann-La Roche Inc. (Nutley, NJ) | See Plans and Pricing |
| MGL-3196 | See Plans and Pricing | Thyroid hormone analogs | Hoffmann-La Roche Inc. (Nutley, NJ) | See Plans and Pricing |
| MGL-3196 | See Plans and Pricing | Prodrugs of thyroid hormone analogs | Hoffmann-La Roche Inc. (Nutley, NJ) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MGL-3196
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MGL-3196 | Argentina | AR092872 | 2032-09-17 | See Plans and Pricing |
| MGL-3196 | Australia | AU2013315017 | 2032-09-17 | See Plans and Pricing |
| MGL-3196 | Brazil | BR112015005891 | 2032-09-17 | See Plans and Pricing |
| MGL-3196 | Canada | CA2884481 | 2032-09-17 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
